Amgen (Nasdaq: AMGN) announced that adding Repatha (evolocumab) to optimized statin therapy resulted in statistically significant regression of atherosclerosis in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE